Harvard Apparatus Regenerative Technology signs exclusive global distribution deal with Health Regen through 2030

Harvard Apparatus Regenerative Technology, Inc.

Exclusive distribution of consumer health/dietary supplements from Nov 1, 2024 to Dec 31, 2030; auto-renews for 6 years if targets met.
Annual sales targets: $1M (2025) escalating to $20M (2030); Company receives 10% markup on manufacturing costs plus pass-through costs.
Early termination by Company triggers penalty of 3x projected annual sales in year 6.
Chinese subsidiary employees and inventory to be transferred to Health Regen effective Nov 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.